SeaSpine Holdings Corporation logo
SeaSpine Holdings Corporation SPNE
report update icon

Quarterly report 2022-Q3
added 05-30-2026

SeaSpine Holdings Corporation Income Statement 2021-2011 | SPNE

Brief overview of financial performance at SeaSpine Holdings Corporation

The conclusions below are based on five years of reported results. Revenue reported by SeaSpine Holdings Corporation was 129 million dollars at the beginning of the period and 191 million dollars at the end. The cumulative result was +48.6%, corresponding to roughly 8.2% per year. The company expanded at a measured pace.

Gross profit changed from 19.1 million dollars to 115 million dollars (+500.9%). Gross margin moved from 14.8% to 59.9%. The expansion indicates stronger pricing power or better control of direct costs.

EBITDA was −$31.7 million at the beginning and −$47 million at the end of the period (−48.2%). EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin was −24.6% at the start and −24.6% at the end. The EBITDA margin stayed near its previous level.

The final result was −9.8 million dollars initially and −54.3 million dollars in the final year. Profitability deteriorated further over the five years.

The five-year change in capitalization reached +435.1%: from $79.6 million to $426 million. Investor expectations increased faster than reported performance.

Summary assessment

The five-year picture requires weighing both strengths and weaknesses. The strongest signals are a stronger gross margin, a larger revenue base and a steady EBITDA margin. Caution is warranted because of a narrow EBITDA buffer and a weaker final result. Investors should continue to monitor margins, costs, and earnings quality.

Annual Income Statement SeaSpine Holdings Corporation

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

426 M 515 M 268 M 236 M 126 M 79.6 M 139 M - - - -

Shares

33.6 M 27.2 M 19 M 15.4 M 12.4 M 11.2 M 11 M 11 M 11 M - -

Historical Prices

12.7 18.9 14.1 15.3 10.1 7.09 12.6 - - - -

Net Income

-54.3 M -43.2 M -8.59 M -9.53 M -7.51 M -9.77 M -55.5 M -24.5 M -25.7 M -30.4 M -

Revenue

191 M 154 M 43.7 M 38 M 132 M 129 M 133 M 139 M 147 M 148 M -

Cost of Revenue

76.9 M 56.8 M 58 M 56 M - - - - - - -

Gross Profit

115 M 97.5 M 28.1 M 23 M 21.5 M 19.1 M 72.1 M 82 M 91.1 M 92.7 M -

Operating Income

-61 M -43.4 M -39.2 M -33.1 M -32.7 M -43.5 M -52.2 M -20.3 M -17.4 M - -

Interest Expense

5.53 M 463 K 302 K -256 K 430 K -264 K -877 K -269 K -4.56 M - -

EBITDA

-47 M -32.7 M -28.9 M -22.4 M -21.8 M -31.7 M -39.7 M -7.39 M -3.87 M -14.4 M -

Operating Expenses

- 140 M 135 M 121 M 113 M 117 M 124 M 102 M 108 M 113 M -

General and Administrative Expenses

42.9 M 35.9 M 33.6 M 30.2 M 97.3 M 101 M 111 M 88.2 M 93 M - -

All numbers in USD currency

Quarterly Income Statement SeaSpine Holdings Corporation

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- 37 M 36.8 M 36.8 M 36.6 M 36.4 M 33.5 M 27.9 M 27.7 M 27.5 M 27.3 M 26.4 M 19.1 M 19.1 M 18.9 M 18.9 M 18.7 M 14.8 M 14.6 M 14.1 M 13.5 M 12.8 M 11.9 M 11.6 M 11.3 M 11.3 M 11.2 M 11.2 M 11.1 M 11.2 M 11 M 11 M - 11 M - - - - - - - - - - - - - -

Net Income

- -15.5 M -13.9 M -16.6 M - -17.6 M -5.21 M -12.7 M -10.3 M -6.57 M -13.7 M -12.6 M -8.59 M -9.66 M -12 M -8.99 M -9.53 M -9.53 M -7.36 M -7.1 M -7.51 M -7.46 M -8.04 M -9.1 M -9.77 M -9.45 M -12 M -12 M -13.8 M -14.2 M -17.7 M -9.9 M -8.24 M -5.32 M -5.43 M -5.56 M - - - - - - - - - - - -

Revenue

- 67.1 M 56.3 M 50.7 M - 46.4 M 47.5 M 42 M 46.4 M 43.2 M 28.6 M 36.1 M 43.7 M 39.9 M 39.3 M 36.2 M 38 M 35.8 M 36.4 M 33.2 M - 31.7 M 34.2 M 31.9 M - 31.7 M 33.2 M 31.4 M - 32.7 M 33.5 M 32.3 M - 33.6 M 35.8 M - - - - - - - - - - - - -

Cost of Revenue

- 26.6 M 19.1 M 20.4 M - 18.3 M 17.5 M 15.4 M - 14.1 M 11.7 M 13.8 M - 14.4 M 14.3 M 13.6 M - 14.2 M 14.6 M 12.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- 40.5 M 37.2 M 30.3 M - 28.2 M 30 M 26.6 M 29.1 M 29.1 M 16.9 M 22.3 M 28.1 M 25.5 M 25 M 22.6 M 23 M 21.6 M 21.8 M 21 M 21.5 M 19.6 M 20.2 M 18.7 M 19.1 M 17.9 M 19.3 M 17.1 M 18.1 M 15.3 M 19 M 19.7 M 20.5 M 19.3 M 20.6 M 21.6 M - - - - - - - - - - - -

Operating Income

- -14.7 M -14.5 M -16.8 M - -18.3 M -11.1 M -12.5 M - -6.65 M -13.7 M -12.7 M - -9.34 M -12 M -9.04 M - -9.45 M -7.17 M -7.05 M - -7.73 M -8.18 M -9.09 M - -9.5 M -12.2 M -12.3 M - -14.7 M -16.1 M -8.32 M - -4.45 M -5.02 M - - - - - - - - - - - - -

Interest Expense

- -419 K -559 K 2 K - -231 K 6.08 M -159 K - 136 K 14 K 227 K - -97 K -25 K 73 K - -190 K -157 K 20 K - 215 K 185 K -13 K - -59 K -232 K 258 K - 195 K -51 K -721 K - -30 K -22 K - - - - - - - - - - - - -

EBITDA

- -1.85 M -6.04 M -12.6 M - -7.99 M -5.25 M -9.79 M - 1.28 M -8.48 M -10.1 M - -1.41 M -6.54 M -6.27 M - -1.5 M -1.9 M -4.41 M - 450 K -2.74 M -6.38 M - -514 K -5.93 M -9.13 M - -14.4 M -10.2 M -5.31 M - 5.41 M 2.21 M - - - - - - - - - - - - -

General and Administrative Expenses

- 14.8 M 12.2 M 10.9 M - 11.6 M 9.99 M 10.4 M - 8.91 M 8.84 M 8.55 M - 30.1 M 27.6 M 27.3 M - 27 M 25.4 M 24.5 M - 23.7 M 24.2 M 24 M - 23.8 M 27 M 25.4 M - 26.3 M 31.7 M 25.1 M - 20.3 M 22.2 M - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company SeaSpine Holdings Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
AxoGen AxoGen
AXGN
$ 48.73 1.42 % $ 2.24 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 18.34 0.55 % $ 1.41 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.86 3.87 % $ 14.6 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 82.22 0.02 % $ 4.48 B britainBritain
LENSAR LENSAR
LNSR
$ 8.2 0.24 % $ 98.1 M usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 - $ 1.16 B usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
MiMedx Group MiMedx Group
MDXG
$ 4.27 1.67 % $ 631 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 15.34 0.1 % $ 434 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.4 10.38 % $ 24.9 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Inogen Inogen
INGN
$ 5.75 0.17 % $ 153 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Butterfly Network Butterfly Network
BFLY
$ 8.84 0.79 % $ 2.18 B usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA